We fight lung cancer together. That’s a lesson we’ve learned and put into action.
Amy C. Moore, PhD, our Director of Science & Research, recently published an article in the International Association for the Study of Lung Cancer online news about the importance of building research models utilizing partnerships between survivor groups, research experts, GO2 Foundation for Lung Cancer, and the Addario Lung Cancer Medical Institute (ALCMI).
In the article, she discusses research related to EGFR-mutant lung cancer. You can start reading here and then click below to read the complete article.
Globally, approximately 140,000 patients per year diagnosed with NSCLC harbor a mutation in the epidermal growth factor receptor (EGFR) gene.1 In the United States, approximately 15% of patients with NSCLC have EGFR mutations, whereas the likelihood is even higher in patients residing in Asia.
The challenge in treating patients with EGFR-mutant lung cancer is that most individuals ultimately develop resistance to tyrosine kinase inhibitors (TKIs), which remain the standard of care. Further, for patients with EGFR or HER2 exon 20 insertions, commercially available TKIs simply fail to work at all. Thus, understanding mechanisms of resistance and developing better therapies is key to improving outcomes for these patients.